Tykerb - 2007 FDA approvals

Drug: Tykerb (lapatinib)
Indication: Metastatic breast cancer
Company: GlaxoSmithKline
Approval Date: March 13, 2007

Scoop: The FDA gave its approval to Tykerb for metastatic breast cancer in combination with Xeloda. Tykerb is also in trials for metastatic brain cancer. Tykerb has an advantage over the blockbuster Herceptin because it is administered in pill form while Herceptin is injected. And data supports that Tykerb in combination with Xeloda is more effective that a treatment consisting only of Xeloda.

More news:
FDA approves Tykerb for breast cancer. Report

Tykerb - 2007 FDA approvals
Read more on

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.